The impact of increasing neurological disability of multiple sclerosis on health utilities: A systematic review of the literature

Journal of Medical Economics

Volumn 13, Issue 1, 2010, Pages 78-89

  Naci, Huseyin ^a   Fleurence, Rachael ^a   Birt, Julie ^b   Duhig, Amy ^b  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

Health utilities; Health related quality of life; Multiple sclerosis

Indexed keywords

EXPANDED DISABILITY STATUS SCALE; HEALTH CARE UTILIZATION; HUMAN; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; REVIEW; SYSTEMATIC REVIEW;

ACTIVITIES OF DAILY LIVING; ALGORITHMS; DISABILITY EVALUATION; DISABLED PERSONS; DISEASE PROGRESSION; GREAT BRITAIN; HEALTH CARE COSTS; HEALTH RESOURCES; HEALTH SERVICES; HEALTH STATUS INDICATORS; HUMANS; MULTIPLE SCLEROSIS; NERVOUS SYSTEM DISEASES; QUALITY OF LIFE; STATISTICS AS TOPIC;

EID: 77149167641     PISSN: 13696998     EISSN: None     Source Type: Journal    
DOI: 10.3111/13696990903543085     Document Type: Review

References (43)

1. De Judicibus MA, McCabe MP. The impact of the financial costs of multiple sclerosis on quality of life. Int J Behav Med 2007;14:3-11.
2. Vollmer T. The natural history of relapses in multiple sclerosis. J Neurol Sci 2007;256:S5-13.
3. Aronson KJ. Quality of life among persons with multiple sclerosis and their caregivers. Neurology 1997;48:74-80.
4. Schumacher GA, Beebe G, Kibler RF, et al. Problems of experimental trials of therapy in multiple sclerosis: report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis. Ann NY Acad Sci 1965;22:552-568.
5. Yorkston KM, Johnson K, Klasner ER, et al. Getting the work done: a qualitative study of individuals with multiple sclerosis. Disabil Rehabil 2003;25:369-379.
6. McCabe MP, De Judicibus M. The effects of economic disadvantage on psychological well-being and quality of life among people with multiple sclerosis. J Health Psychol 2005;10:163-173.
7. Stolp-Smith KA, Atkinson EJ, Campion ME, et al. Health care utilization in multiple sclerosis: a population-based study in Olmsted County, MN. Neurology 1998;50:1594-1600.
8. Ford HL, Gerry E, Johnson MH, et al. Health status and quality of life of people with multiple sclerosis. Disabil Rehabil 2001;23:516-521.
9. Miltenburger C, Kobelt G. Quality of life and cost of multiple sclerosis (Provisional record). Clin Neurol Neurosurg 2002;104:272-275.
10. Rothwell PM, McDowell Z, Wong CK, et al. Doctors and patients don't agree: cross sectional study of patients' and doctors' perceptions and assessments of disability in multiple sclerosis. Br Med J 1997;314:1580-1583.
11. Drummond M, Sculpher M, Torrance G, et al. Methods for the Economic Evaluation of Health Care Programmes, 3rd edn. Oxford: Oxford University Press, 2005.
12. NICE. Guide to the methods of technology appraisal. [online]. 2008. Available from URL: http://www.nice.org.uk/media/B52/A7/ TAMethodsGuideUpdatedJune2008.pdf [Accessed 2008 January 29].
13. EuroQol Group. EQ-5D: A standardised instrument for use as a measure of health outcome. [online]. Available from URL: http://www.euroqol.org/ [Accessed 2008 8 December].
14. Furlong W, Feeny D, Torrance G, et al. The Health Utilities Index system for assessing health-related quality of life in clinical studies. Ann Med 2001;33:375-384.
15. Furlong W, Feeny D, Torrance G, et al. Multiplicative multi-attribute utility function for the Health Utilities Index Mark 3 (HUI3) system: a technical report: McMaster University, 1998.
16. The University of Sheffield, Department of Health Economics and Decision Science. About the SF-6D. [online]. 2008. Available from URL: http://www.shef.ac.uk/scharr/sections/heds/mvh/sf-6d [Accessed 2008 8 December].
17. Orme M, Kerrigan J, Tyas D, et al. The effect of disease, functional status, and relapses on the utility of people with multiple sclerosis in the UK. Value Health 2007;10:54-60.
18. Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life of multiple sclerosis in the United Kingdom (Brief record). Eur J Health Econ 2006;7:S96-104.
19. Parkin D, Jacoby A, McNamee P, et al. Treatment of multiple sclerosis with interferon (beta): an appraisal of cost-effectiveness and quality of life. J Neurol Neurosurg Psychiatry 2000;68: 144-149.
20. Forbes RB, Lees A, Waugh N, et al. Population based cost utility study of interferon beta-1b in secondary progressive multiple sclerosis. Br Med J 1999;319:1529-1533.
21. Grima DT, Torrance GW, Francis G, et al. Cost and health related quality of life consequences of multiple sclerosis (Provisional record). Multiple Sclerosis 2000;6:91-98.
22. Jones CA, Pohar SL, Warren S, et al. The burden of multiple sclerosis: a community health survey. Health Qual Life Outcomes 2008;6:1.
23. Fisk JD, Brown MG, Sketris IS, et al. A comparison of health utility measures for the evaluation of multiple sclerosis treatments. J Neurol Neurosurg Psychiatry 2005;76:58-63.
24. Kobelt G, Lindgren P, Smala A, et al. Costs and quality of life in multiple sclerosis. An observational study in Germany. HEPAC Health Economics in Prevention and Care 2001;2:60-68.
25. Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life of multiple sclerosis in Germany. Eur J Health Econ 2006;7:534-544.
26. Berg J, Lindgren P, Fredrikson S, et al. Costs and quality of life of multiple sclerosis in Sweden. Eur J Health Econ 2006;7:S75-85.
27. Henriksson F, Fredrikson S, Masterman T, et al. Costs, quality of life and disease severity in multiple sclerosis: a cross-sectional study in Sweden. Eur J Neurol 2001;8:27-35.
28. Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life of multiple sclerosis in Austria. Eur J Health Econ 2006;7: 514-523.
29. Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life for patients with multiple sclerosis in Belgium. Eur J Health Econ 2006;7:S24-33.
30. Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life of multiple sclerosis in Italy. Eur J Health Econ 2006;7:S45-54.
31. Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life in multiple sclerosis in The Netherlands. Eur J Health Econ 2006;7:S55-64.
32. Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life of multiple sclerosis in Spain. Eur J Health Econ 2006;7:S65-74.
33. Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life of multiple sclerosis in Switzerland. Eur J Health Econ 2006;7:S86-95.
34. Prosser LA, Kuntz KM, Bar-Or A, et al. Patient and community preferences for treatments and health states in multiple sclerosis. Mult Scler 2003;9:311-319.
35. Dolan P, Gudex C, Kind P, et al. A Social Tariff for EuroQol: Results from a UK General Population Survey. York, UK: Center for Health Economics, University of York, 1995.
36. McAlpine D, Compston N. Some aspects of the natural history of disseminated sclerosis. QJM 1952;21:135-167.
37. Atlas of MS Database. Global Prevalence of MS [online]. 2009. Available from URL: http://www.atlasofms.org/index.aspx [Accessed 2009 March 11].
38. Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life in multiple sclerosis in Europe: method of assessment and analysis (provisional record). Eur J Health Econ 2006;7:S5-13.
39. Coughlin SS. Recall bias in epidemiologic studies. J Clin Epidemiol 1990;43:87-91.
40. Brazier J. Valuing health states for use in cost-effectiveness analysis. Pharmacoeconomics 2008;26:769-779.
41. Dolan P, Sutton M. Mapping visual analogue and standard gamble utilities. Soc Sci Med 1997;44:1519-1530.
42. Gruenewald DA, Higginson IJ, Vivat B, et al. Quality of life measures for the palliative care of people severely affected by multiple sclerosis: a systematic review. Mult Scler 2004;10:251-255.
43. Gold MR, Siegel JE, Russell LB, et al. Cost Effectiveness in Health and Medicine. New York: Oxford University Press, 1996.